Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
5
×
boston blog main
boston top stories
life sciences
national blog main
clinical trials
national top stories
deals
new york blog main
new york top stories
san francisco blog main
blackstone group
david goldstein
depression
epilepsy
essential tremor
fda
hepatitis b
kiran reddy
major depressive disorder
perimenopausal depression
praxis precision medicines
san francisco top stories
startups
steven petrou
abbvie
alexion pharmaceuticals
aligos therapeutics
allergan
alnylam pharmaceuticals
alzheimer's disease
antisense oligonucleotide
azacitidine
baker brothers life sciences
benzodiazepine
benzodiazepines
beta-thalassemia
biogen
biotech ipos
What
medicines
research
5
×
drugs
aims
biotech
gene
genetic
new
praxis
precision
stop
abbvie
alliance
approach
backed
based
biotechs
called
caught
cause
causing
central
ceo
cns
debuts
developing
dicerna
disease
disorder
drug
editas
editing
emerged
epigenetic
epigenetics
epilepsy
exits
experimental
eye
field
Language
unset
Current search:
boston
×
research
×
@xconomy.com
3 years ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further